COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,557 Articles (22,400 medRxiv, 8,157 bioRxiv)

Most recent first Previous |  Page 842: Articles 8411-8420  | Next

Omicron and Alpha P680H block SARS-CoV2 spike protein from accessing cholinergic inflammatory pathway via α9-nAChR mitigating the risk of MIS-C
Camacho, C. J., Santiago, U.
10.1101/2022.02.18.481096 — Posted: 2022-02-24
Discovery and functional interrogation of SARS-CoV-2 protein-RNA interactions
Xiang, J. S., Mueller, J. R., Luo, E.-C., Yee, B. A., Schafer, D., Schmok, J. C., Tan, F. E., Rothamel, K., McVicar, R. N., Kwong, E. M., Jones, K. L., Her, H.-L., Chen, C.-Y., Vu, A. Q., Jin, W., Park, S. S., Le, P., Brannan, K. W., Kofman, E. R., Li, Y., Tankka, A. T., Dong, K. D., Song, Y., Carlin, A. F., Van Nostrand, E. L., Leibel, S. L., Yeo, G. W.
10.1101/2022.02.21.481223 — Posted: 2022-02-24
Characterization of various remdesivir-resistant mutations of SARS-CoV-2 by mathematical modeling and molecular dynamics simulation.
Torii, S., Kim, K. S., Koseki, J., Suzuki, R., Iwanami, S., Fujita, Y., Jeong, Y. D., Matsuura, Y., Shimamura, T., Iwami, S., Fukuhara, T.
10.1101/2022.02.22.481436 — Posted: 2022-02-24
A single-dose of the deactivated rabies virus vectored COVID-19 vaccine, CORAVAX, is highly efficacious and alleviates lung inflammation in the hamster model.
Schnell, M. J.
10.1101/2022.02.21.481324 — Posted: 2022-02-24
Biophysical fitness landscape of the SARS-CoV-2 Delta variant receptor binding domain
Patrick, C., Upadhyay, V., Lucas, A., Mallela, K.
10.1101/2022.02.21.481311 — Posted: 2022-02-23
Confirming Multiplex Q-PCR Use in COVID-19 with Next Generation Sequencing: Strategies for Epidemiological Advantage
Carpenter, R. E., Tamrakar, V. K., Chahar, H. S., Vine, T., Sharma, R.
10.1101/2022.02.22.481485 — Posted: 2022-02-23
Potent Neutralizing Activity of Polyclonal Equine Antibodies against Omicron SARS-CoV-2
Luczkowiak, J., Radreau, P., Nguyen, L., Labiod, N., Lasala, F., Herbreteau-Delale, C., Delgado, R.
10.1101/2022.02.21.481341 — Posted: 2022-02-23
Serological screening in wild ruminants in Germany, 2021/22: No evidence of SARS-CoV-2, bluetongue virus or pestivirus spread but high seroprevalences against Schmallenberg virus
Wernike, K., Fischer, L., Holsteg, M., Aebischer, A., Petrov, A., Marquart, K., Schotte, U., Schoen, J., Hoffmann, D., Hechinger, S., Neubauer-Juric, A., Blicke, J., Mettenleiter, T. C., Beer, M.
10.1101/2022.02.21.481262 — Posted: 2022-02-23
Mucosal Immunization of Cynomolgus Macaques with Adenoviral Vector Vaccine Elicits Neutralizing Nasal and Serum Antibody to Several SARS-CoV-2 Variants
Flitter, B. A., Lester, C. A., Tedjakusuma, S. N., Dora, E. G., Peinovich, N., Cortese, M., Martinez, C. I., Jegede, C. B., Neuhaus, E. D., Tucker, S. N.
10.1101/2022.02.21.481345 — Posted: 2022-02-23
SARS-CoV-2 Variant Delta Potently Suppresses Innate Immune Response and Evades Interferon-Activated Antiviral Responses
Tandel, D., Sah, V., Singh, N. K., Potharaju, P. S., Gupta, D., Shrivastava, S., Sowpati, D. T., Harshan, K. H.
10.1101/2022.02.22.481430 — Posted: 2022-02-23

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).